Establishment of a risk score model for bladder urothelial carcinoma based on energy metabolism‐related genes and their relationships with immune infiltration
FEBS Open Bio · 2023
DOI: 10.1002/2211-5463.13580 ↗Kurz gefasst
Fachartikel in der Zeitschrift FEBS Open Bio, 2023. Verfasst von Caihong Huang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Center for Genomic and Personalized Medicine, Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center f…. Hauptthemen laut MEDLINE: Carcinoma, Transitional Cell, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Bladder urothelial carcinoma (BLCA) is a common malignant tumor of the human urinary system, and a large proportion of BLCA patients have a poor prognosis. Therefore, there is an urgent need to find more efficient and sensitive biomarkers for the prognosis of BLCA patients in clinical practice. RNA sequencing (RNA‐seq) data and clinical information were obtained from The Cancer Genome Atlas, and 584 energy metabolism‐related genes (EMRGs) were obtained from the Reactome pathway database. Cox regression analysis and least absolute shrinkage and selection operator analysis were applied to assess prognostic genes and build a risk score model. The estimate and cibersort algorithms were used to explore the immune microenvironment, immune infiltration, and checkpoints in BLCA patients. Furthermore, we used the Human Protein Atlas database and our single‐cell RNA‐seq datasets of BLCA patients to verify the expression of 13 EMRGs at the protein and single‐cell levels. We constructed a risk score model; the area under the curve of the model at 5 years was 0.792. The risk score was significantly correlated with the immune markers M0 macrophages, M2 macrophages, CD8 T cells, follicular helper T cells, regulatory T cells, and dendritic activating cells. Furthermore, eight immune checkpoint genes were significantly upregulated in the high‐risk group. The risk score model can accurately predict the prognosis of BLCA patients and has clinical application value. In addition, according to the differences in immune infiltration and checkpoints, BLCA patients with the most significant benefit can be selected for immune checkpoint inhibitor therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Genomic and Personalized Medicine, Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Guangxi Medical University, Nann…
- Department of Urology, Institute of Urology and Nephrology, First Affiliated Hospital of Guangxi Medical University, Nanning, China.
- School of Public Health, Guangxi Medical University, Nanning, China.
ORCID-Profile: Longman Li
Zitieren
APA
Huang, C., Li, Y., Ling, Q., Wei, C., Fang, B., Mao, X., Yang, R., Zhang, L., Huang, S., Cheng, J., Liao, N., Wang, F., Mo, L., Mo, Z., & Li, L. (2023). Establishment of a risk score model for bladder urothelial carcinoma based on energy metabolism‐related genes and their relationships with immune infiltration. FEBS Open Bio. https://doi.org/10.1002/2211-5463.13580
Vancouver
Huang C, Li Y, Ling Q, Wei C, Fang B, Mao X, et al. Establishment of a risk score model for bladder urothelial carcinoma based on energy metabolism‐related genes and their relationships with immune infiltration. FEBS Open Bio. 2023. doi:10.1002/2211-5463.13580
BibTeX
@article{Huang2023,
author = {Huang, Caihong and Li, Yexin and Ling, Qiang and Wei, Chunmeng and Fang, Bo and Mao, Xingning and Yang, Rirong and Zhang, LuLu and Huang, Shengzhu and Cheng, Jiwen and Liao, Naikai and Wang, Fubo and Mo, Linjian and Mo, Zengnan and Li, Longman},
title = {Establishment of a risk score model for bladder urothelial carcinoma based on energy metabolism‐related genes and their relationships with immune infiltration},
journal = {FEBS Open Bio},
year = {2023},
doi = {10.1002/2211-5463.13580}
}
EUVIMED